NDTV-Dettol Banega Swasth Swachh India NDTV-Dettol Banega Swasth Swachh India
  • Home/
  • News/
  • Phase-I Human Clinical Trial Of Potential COVID-19 Vaccine: Man Given First Dose At AIIMS


Phase-I Human Clinical Trial Of Potential COVID-19 Vaccine: Man Given First Dose At AIIMS

According to a Professor at AIIMS, Delhi, the first volunteer for the human trial of the COVID-19 vaccine candidate Covaxin is a resident of Delhi and over 3,500 volunteers have registered themselves for the trial

Phase-I Human Clinical Trial Of Potential COVID-19 Vaccine: Man Given First Dose At AIIMS
  • The first human trial volunteer in Delhi will be monitored for 7 days
  • ICMR has selected 12 sites for conducting phase I and II trials of Covaxin
  • In phase I, the vaccine would be tested on 375 volunteers

New Delhi: The phase-I human clinical trial of India’s first indigenously-developed vaccine against novel coronavirus, Covaxin, began at the AIIMS (All India Institute Of Medical Science) on Friday with the first dose of the injection given to a man, who is in his 30s. Already, over 3,500 volunteers have registered themselves for the trial at AIIMS since last Saturday, of whom the screening of at least 22 people is underway, said Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS and the principal investigator of the study.

Also Read: Coronavirus Vaccine: Oxford University’s COVID-19 Vaccine Candidate Exhibits Strong Immune Responses, Says The Lancet Study

Dr Sanjay Rai said that first volunteer is a resident of Delhi who was screened two days ago and all his health parameters were found to be within the normal range. He also does not have any co-morbid conditions. He said,

The first dose of 0.5 ml intramuscular injection was given to him around 1.30 pm. No immediate side-effects have been observed so far. He was under observation for two hours and will be monitored for the next seven days.

Few more participants would be given the vaccine on Saturday after their screening reports come. AIIMS-Delhi is among the 12 sites selected by the Indian Council for Medical Research (ICMR) for conducting phase I and II randomised, double-blind, placebo-controlled clinical trials of Covaxin.

Also Read: India ‘Pharmacy Of The World’, On Fast-Track Mode To Develop COVID-19 Vaccine: Indian Council of Medical Research

In phase I, the vaccine would be tested on 375 volunteers and the maximum of 100 of them would be from AIIMS. The second phase would include around 750 volunteers from all 12 sites together, Rai said. Phase I of the vaccine trial will be done on healthy people aged 18-55 years having no co-morbid conditions. Women with no pregnancy will also be selected to be a part of the trial in the first phase. In the second phase, 750 people will be recruited between 12-65 years, AIIMS Director Dr Randeep Guleria had said.

Already, around 1,800 volunteers have registered themselves for the trial at AIIMS, he had said.

In the first phase we see the safety of the vaccine which is of primary importance and the dose range is also calculated, he said.

There are three formulations of the vaccine, and each subject will be given any one of the formulation in two doses two weeks apart. The first 50 will get the lowest strength dose of the vaccine. If it is found to be safe in them, then it will be given to another 50 patients in high doses, according to Rai. COVID-19 vaccine candidate Covaxin, developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV), had recently got the nod for human clinical trials from the Drugs Controller General of India (DCGI).

Also Read: Serum Institute To Produce COVID-19 Vaccine Candidate Developed By Oxford University, Will Be Called Covishield In India

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene


This website follows the DNPA Code of Ethics

© Copyright NDTV Convergence Limited 2024. All rights reserved.